A groundbreaking revelation: Immune checkpoint inhibitors (ICIs) offer a glimmer of hope for patients battling two formidable foes, HIV and non-small cell lung cancer (NSCLC). But is it safe?
Recent research reveals that ICIs can be safely administered to patients with both HIV and NSCLC, but there's a catch. While the treatment shows promise, the scientific community has largely overlooked this vulnerable population in clinical trials. This review aims to shed light on the matter and advocate for their inclusion.
The Review's Findings:
In a comprehensive analysis of studies published between 2015 and 2025, researchers focused on the safety of ICIs in HIV-positive NSCLC patients. The review included retrospective, registry, and clinical prospective studies, but excluded case reports. Five studies made the cut, each offering a unique perspective.
The first study, from the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International Consortium, compared 61 HIV-positive patients with metastatic NSCLC to a control group without HIV. The results? No significant differences in progression-free survival, overall response rate, or overall survival. Interestingly, immune-related adverse events were slightly higher in the HIV group (22% vs. 20%).
Another study assessed nivolumab's effectiveness in 16 HIV-positive patients with advanced NSCLC. All patients were on antiretroviral therapy (ART) and had received chemotherapy before immunotherapy. The disease control rate was promising at 62.5% after 8 weeks, but 5 patients experienced progressive disease. Mild to moderate treatment-related side effects were reported.
A French retrospective sub-analysis of the CANCERVIH registry included 21 patients with HIV and NSCLC, with 55% receiving ICIs as a second-line treatment. Nivolumab monotherapy was the preferred choice. The median survival was 10.7 months, and the disease control rate was 42.9%.
The OncoVIHAC ANRS CO24 study, a French prospective observational cohort, involved 65 patients with lung cancer and HIV. The 18-month overall survival estimate was 36.4%, and progression-free survival was 25.5%. Notably, 15.4% of patients experienced severe immune-related adverse events. Most patients who were virally suppressed at the study's start remained so by the end.
The PACIFIC trial, which evaluated durvalumab in HIV-negative patients with stage III NSCLC, included just one HIV-positive patient with stage IIIB lung adenocarcinoma. This patient experienced tumor shrinkage when taking durvalumab alongside chemoradiotherapy, but discontinued due to disease progression after 4 months.
Controversy and Limitations:
The review highlights a critical issue: the exclusion of HIV-positive patients from ICI trials. This raises ethical questions about representation and access to potentially life-saving treatments. But here's where it gets controversial—the review itself has limitations. Most data came from small, retrospective, non-randomized trials, which may impact the generalizability of the findings.
The researchers emphasize the need for interdisciplinary collaboration between oncologists and HIV specialists. They also stress the importance of managing ART, monitoring immune status, and considering potential drug interactions. However, the lack of data on dual checkpoint blockade remains a concern.
The Bigger Picture:
This review is a step forward in understanding the safety of ICIs in HIV-positive NSCLC patients. But the journey doesn't end here. More research is needed to ensure these patients receive the best possible care. The question remains: How can we bridge the gap between promising treatments and those who need them most?
What do you think? Are we doing enough to include underrepresented populations in clinical trials? Share your thoughts in the comments below and let's spark a conversation about this critical issue.
